|
|
||||||||||||||
|
|
|||||||||||||||
a Department of
Pathophysiology, University of Athens School of Medicine, Athens,
Greece, b Clinical and Molecular
Epidemiology Unit, Department of Hygiene and Epidemiology, University
of Ioannina School of Medicine, Ioannina, Greece, c Department of Nuclear Medicine, Laikon
General Hospital, Athens, Greece
Correspondence to: Professor Moutsopoulos, Department of Pathophysiology, School of Medicine, National University of Athens, 75 Mikras Asias St, 115 27, Athens, Greece
Accepted for publication 22 November 1999
OBJECTIVE
To study the
prevalence of different causes of anaemia in patients with systemic
lupus erythematosus (SLE) and their associations with immunological and
clinical parameters and to evaluate the contribution of erythropoietin
(Epo) and anti-erythropoietin (anti-Epo) autoantibodies to the
development of SLE anaemia.
METHODS
132 SLE
patients with anaemia (defined as haemoglobin of 12 g/dl or less for
women and 13.5 g/dl or less for men) from among a total of 345 consecutive SLE patients were prospectively enrolled into the study.
Standard haematological and immunological tests were performed and
serum Epo and anti-Epo antibodies were assayed.
RESULTS
The identified
causes were anaemia of chronic disease (ACD) n=49 (37.1%), iron
deficiency anaemia (IDA) n=47 (35.6%), autoimmune haemolytic anaemia
(AHA) n=19 (14.4%) and other causes n=17 (12.9%). There was
significant heterogeneity in the severity of anaemia between the four
groups (p<0.01) with AHA cases being on average more severe. The
proportion of patients with anticardiolipin antibodies, low
complement levels and anti-dsDNA differed significantly among the four
groups; these markers were particularly common in patients with AHA,
and uncommon in patients with IDA. Twenty one of 100 tested patients
had anti-Epo antibodies. Such antibodies were seen practically only in
patients with ACD (odds ratio 3.1, p=0.041) and in patients with high
lupus activity (ECLAM) scores (odds ratio 1.27 per point, p=0.055). Epo
response was inadequate in 42.4% and 41.2% of patients with ACD and
AHA, respectively.
CONCLUSIONS
Anaemia in
SLE usually takes the form of ACD and IDA, however autoimmune
haemolysis is not uncommon. SLE patients with different causes of
anaemia differ in regard to several immunological parameters. Epo
response is blunted in anaemic SLE patients, particularly those with
ACD and AHA.
This article has been cited by other articles:
![]() |
J. Grisar, C. W. Steiner, M. Bonelli, T. Karonitsch, I. Schwarzinger, G. Weigel, G. Steiner, and J. S. Smolen Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells Rheumatology, October 1, 2008; 47(10): 1476 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Bertoli, L. M. Vila, M. Apte, B. J. Fessler, H. M. Bastian, J. D. Reveille, G. S. Alarcon, and for the LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual Rheumatology, September 1, 2007; 46(9): 1471 - 1476. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Manenti and A. Vaglio Pure red cell aplasia followed by disseminated intravascular coagulation in a haemodialysis patient receiving erythropoietin-{beta} Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1465 - 1467. [Full Text] [PDF] |
||||
![]() |
S Giannouli, M Voulgarelis, P D Ziakas, and A G Tzioufas Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment Ann Rheum Dis, February 1, 2006; 65(2): 144 - 148. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |